Trials / Completed
CompletedNCT00593606
Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine
A Phase 3b, Open-Label, Multicenter Trial to Assess the Safety and Tolerability of Switching Korean Subjects From Ropinirole to the Rotigotine Transdermal System and Its Effect on Symptoms in Idiopathic Parkinson's Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 124 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 3b, open-label, multicenter trial to assess the safety and tolerability of switching from ropinirole therapy to the rotigotine transdermal system and its effect on symptoms in subjects with idiopathic Parkinson's disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rotigotine | Strength: 2,4,6,and 8mg/24h, form: transdermal application, once daily application |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2008-01-15
- Last updated
- 2014-10-02
- Results posted
- 2009-05-27
Source: ClinicalTrials.gov record NCT00593606. Inclusion in this directory is not an endorsement.